EP2665702A1 - Process for the preparation of retigabine - Google Patents

Process for the preparation of retigabine

Info

Publication number
EP2665702A1
EP2665702A1 EP12700199.8A EP12700199A EP2665702A1 EP 2665702 A1 EP2665702 A1 EP 2665702A1 EP 12700199 A EP12700199 A EP 12700199A EP 2665702 A1 EP2665702 A1 EP 2665702A1
Authority
EP
European Patent Office
Prior art keywords
retigabine
compound
formula
preparation
salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP12700199.8A
Other languages
German (de)
French (fr)
Inventor
Russ N FITZGERALD
Alan Millar
Jennifer Fell Toczko
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/EP2011/050633 external-priority patent/WO2011089126A2/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Priority to EP12700199.8A priority Critical patent/EP2665702A1/en
Priority claimed from PCT/EP2012/050559 external-priority patent/WO2012098075A1/en
Publication of EP2665702A1 publication Critical patent/EP2665702A1/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C269/00—Preparation of derivatives of carbamic acid, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C269/04—Preparation of derivatives of carbamic acid, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups from amines with formation of carbamate groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C209/00—Preparation of compounds containing amino groups bound to a carbon skeleton
    • C07C209/24—Preparation of compounds containing amino groups bound to a carbon skeleton by reductive alkylation of ammonia, amines or compounds having groups reducible to amino groups, with carbonyl compounds
    • C07C209/28—Preparation of compounds containing amino groups bound to a carbon skeleton by reductive alkylation of ammonia, amines or compounds having groups reducible to amino groups, with carbonyl compounds by reduction with other reducing agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C269/00—Preparation of derivatives of carbamic acid, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C269/06—Preparation of derivatives of carbamic acid, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups by reactions not involving the formation of carbamate groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Definitions

  • This invention relates to a novel chemical process for the synthesis of 2- ethyoxycarbonylamino-5-(4-fluorobenzylamino)-nitrobenzene and its use in the preparation of 2-amino-4-(4-fluorobenzylamino)-1-ethoxycarbonylaminobenzene (retigabine/ezogabine) and its polymorphic forms thereof.
  • a novel, simplified and economic process has now been found for making 2- ethoxycarbonylamino-5-(4-fluorobenzylamino)-nitrobenzene.
  • a further aspect of the invention is the preparation of retigabine using 2-ethoxycarbonylamino-5-(4- fluorobenzylamino)-nitrobenzene so made. Retigabine may then be optionally crystallised into one of its polymorphic forms.
  • the term "base” is intended to mean any substance that can act as a proton acceptor.
  • the base is a strong base.
  • the bases may be selected from sodium ethoxide, sodium hydride, potassium tert-butoxide, n-butyl lithium, potassium hexamethyldisilylazide (KHMDS), cesium carbonate, potassium hydroxide, sodium pentoxide, sodium tert-butoxide, lithium ethoxide, sodium hydroxide, potassium ethoxide, diisopropyl ethyl amine (DIPEA), 1 ,8-diazabicylco[5.4.0]undec-7-ene (DBU), 1 ,4-diazabicyclo[2.2.2]octane (DABCO) or lithium tert-butoxide.
  • the base is sodium ethoxide.
  • the base is present in range of 1.8 to 2.2 molar equivalents.
  • the base is neutralized with an acid.
  • the acid is any organic or mineral acid.
  • the acid is acetic acid.
  • the acid is present in range of 1.8 to 2.2 molar equivalents.
  • diethylcarbonate is present in the range of 5 to 7 molar equivalents. In one embodiment the reaction temperature is in the range 15 to 30°C.
  • reaction time is in the range 1.5 to 24 hours.
  • the compound of formula (II) may be prepared by the reaction of 4-fluorobenzaldehyde and 4-amino-2-nitroaniline followed by reduction using standard procedures for example using NaBH 4 in solution in NaOH or n-methylpyrrolidine (NMP). Other common boron, aluminium or metal hydride reducing agents may be used.
  • a solvent used for the above reaction can be selected from an alcohol, for example ethanol or isopropanol (I PA).
  • the alcohol may be denatured.
  • the compound of formula (II) may be isolated in crystalline form by the addition of a counter solvent for example water.
  • a process for the preparation of a compound of formula (I) or a salt thereof which comprises the following steps: reaction of 4-fluorobenzaldehyde and 4-amino-2-nitroaniline followed by reduction using standard procedures to produce a compound of formula (II); and
  • a process for the preparation of retigabine, or a salt thereof which comprises the following steps: reacting a compound of formula (II) with diethylcarbonate in the presence of a base to produce a compound of formula (I), or a salt thereof; and reduction of compound of formula (I) using standard procedures to produce retigabine;
  • the present process for the preparation of retigabine allows for a better control of impurity levels and has fewer steps providing better cost of goods.
  • the above processes for the preparation of retigabine may further include the preparation of retigabine polymorphic Form A, Form B or Form C, preferably Form A.
  • a retigabine solvent mixture may be seeded with retigabine of the desired polymorphic form in order to enhance recrystallisation.
  • a process for the preparation of polymorphic Forms A, B or C of retigabine which comprises the following steps: reacting a compound of formula (II) with diethylcarbonate with a base to produce a compound of formula (I), or a salt thereof; and
  • preparing retigabine in polymorphic form optionally including the additional step of seeding the retigabine solvent mixture with retigabine Polymorphic Form A, B or C.
  • preparing retigabine in polymorphic form optionally including the additional step of seeding the retigabine solvent mixture with retigabine Polymorphic Form A, B or C.
  • Retigabine and the compounds of formulas (I), (II) and (III), can form acid addition salts thereof.
  • Suitable pharmaceutically acceptable salts will be apparent to those skilled in the art and include those described in J. Pharm. Sci., 1977, 66, 1-19, such as acid addition salts formed with inorganic acids e.g. hydrochloric, hydrobromic, sulfuric, nitric or phosphoric acid; and organic acids e.g. succinic, maleic, acetic, fumaric, citric, tartaric, benzoic, p-toluenesulfonic, methanesulfonic or naphthalenesulfonic acid.
  • inorganic acids e.g. hydrochloric, hydrobromic, sulfuric, nitric or phosphoric acid
  • organic acids e.g. succinic, maleic, acetic, fumaric, citric, tartaric, benzoic, p-toluenesulfonic,
  • a vessel was charged with 4-(4-fluorobenzylamino)-2-nitroaniline (1.0 equiv.; 1.0 wt), NaOEt (2.0 equiv.; 0.52 wt), and diethylcarbonate (DEC) (7 vol).
  • the heterogeneous mixture was stirred at 20-25 °C for 1.5 h or until complete by HPLC.
  • Acetic acid 2.0 equiv
  • H 2 0 and n-BuOH were added to the mixture and the layers were separated.
  • the organic mixture was concentrated under vacuum and n-BuOH was added and distilled via constant volume distillation. The distillation was continued until the desired ratio was obtained.
  • n-BuOH was added and the mixture was adjusted to 60-65 °C to dissolve all solids.
  • the batch temperature was adjusted to 50°C and seeded with 2-ethoxycarbonylamino-5-(4- fluorobenzylamino)-nitrobenzene.
  • the suspension was stirred at 50°C and then cooled to 0°C.
  • the solid was filtered and washed with cold n-BuOH. The solid was dried under reduced pressure at 20-40 °C.
  • a pressure vessel was charged with 2-ethyoxycarbonylamino-5-(4-fluorobenzylamino)- nitrobenzene, 1 kg (1 wt), and the catalyst, 1 % Pt + 2 % V/C, 50 g (0.05 wt).
  • the vessel was pressure test with nitrogen to 6 barg.
  • the reactor was charged with denatured ethanol, 10 L (10 vol), and the stir rate was set to > 450 rpm.
  • the vessel was pressure purged 3 times with nitrogen to 2 barg.
  • the reaction mixture was heated to 50 °C under reactor control. Once an internal temperature of 50 °C was achieved, agitation was discontinued and the reactor purged three times with hydrogen to 2 barg.
  • the batch was cooled to 50 °C and seeded with retigabine (API), 5 g (0.005 wt) slurried in denatured ethanol, 20 ml_ (0.02 vol). After charging the seed, the solution was immediately cooled to 40 °C over 40 minutes, then aged for 60 min. The solution was cooled to 0 °C over 2 hours. The heterogeneous solution was stirred at 0 °C for 1 hour. The batch was milled, isolated and dried. The slurry was transferred to a filter and filtered. The wet cake was transferred to the vacuum oven and dried at 30-40 °C until the LOD indicated ⁇ 0.5 % wt. loss (120 °C for 15 minutes).
  • API retigabine
  • a reaction vessel was charged with denatured ethanol (7.0 volumes) and retigabine (1 wt) was added and the heated to 65-75 °C to dissolve, and stirred for 30 minutes.
  • the solution was filtered to clarify with the temperature maintained above 60 °C throughout the filtration process to avoid precipitation of product.
  • the reactor was rinsed and lined with 1 volume of denatured ethanol. After filtration, the filtered solution was reheated to 60-70 °C to ensure dissolution. The solution was cooled to 54-57 °C (55 °C) and temperature of the contents stabilized.
  • the solution was cooled to 48-53 °C, and upon reaching the desired temperature range, seeded with 0.5 wt% of Form A wet-milled seeds as a slurry in denatured ethanol (0.02 vol) at room temperature.
  • the seed pot was washed with 0.02 vol denatured ethanol.
  • the slurry was cooled to 30-40 °C (35 °C) and held for 60 minutes.
  • the slurry was then cooled to -5 °C to 5 °C at up to 0.5 °C/min.
  • the particle size was reduced using a wet mill on a reactor recirculation loop.
  • the batch was heated to about 35 °C and then cooled to 0 °C and held for 30 min up to 24 hours.
  • the slurry was charged to a filter dryer and settled for 30 min.
  • the mother liquors were removed and the filter cake was washed with cold (0 °C ethanol wash) (2.0 volumes of denatured ethanol). Retigabine was isolated from the filter drier and was placed in appropriate containers.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

This invention relates to a novel chemical process for the synthesis of 2-ethyoxycarbonylamino-5-(4-fluorobenzylamino)-nitrobenzene and its use in the preparation of 2-amino-4-(4-fluorobenzylamino)-1-ethoxycarbonylaminobenzene (retigabine/ezogabine) and its polymorphic forms thereof.

Description

PROCESS FOR THE PREPARATION OF RETIGABINE
This invention relates to a novel chemical process for the synthesis of 2- ethyoxycarbonylamino-5-(4-fluorobenzylamino)-nitrobenzene and its use in the preparation of 2-amino-4-(4-fluorobenzylamino)-1-ethoxycarbonylaminobenzene (retigabine/ezogabine) and its polymorphic forms thereof.
Background 2-Amino-4-(4-fluorobenzylamino)-1-ethoxycarbonylaminobenzene (which is known by the INN name retigabine, or its USAN name ezogabine) is disclosed in US 5,384,330 and EP 0554 543. US 5,384,330 discloses compounds which, can for example, be used as anti-epileptic, muscle-relaxing, fever-reducing and peripherally analgesically acting medications. Drugs of the future 1995 (2) 11 : 1112-11 15 discloses a preparation of retigabine (D-23129). WO98/031663 (US 6538151) discloses 3 different pure crystal modifications, called A, B and C. WO2010/009433 and US2010/0323016 disclose modified release formulations of retigabine. Marketing approval for retigabine as an adjunctive treatment of partial seizures has been granted in Europe and is currently being sought in the US, and other countries.
US 5,384,330 describes two processes for making retigabine designated therein as Variant A and Variant B.
Summary of the Invention
A novel, simplified and economic process has now been found for making 2- ethoxycarbonylamino-5-(4-fluorobenzylamino)-nitrobenzene. A further aspect of the invention is the preparation of retigabine using 2-ethoxycarbonylamino-5-(4- fluorobenzylamino)-nitrobenzene so made. Retigabine may then be optionally crystallised into one of its polymorphic forms.
In a first aspect of the invention there is therefore provided a process for the production of 2-ethoxycarbonylamino-5-(4-fluorobenzylamino)-nitrobenzene (a compound of formula (I)) or a salt thereof:
which comprises reacting 4-(4-fluorobenzylamino)-2-nitroaniline (the compound of formula (II))
with diethylcarbonate in the presence of a base and optionally preparing a salt thereof.
The use of diethylcarbonate results in a more selective carbamylation of a compound of formula (II). The term "base" is intended to mean any substance that can act as a proton acceptor. In one embodiment the base is a strong base. The bases may be selected from sodium ethoxide, sodium hydride, potassium tert-butoxide, n-butyl lithium, potassium hexamethyldisilylazide (KHMDS), cesium carbonate, potassium hydroxide, sodium pentoxide, sodium tert-butoxide, lithium ethoxide, sodium hydroxide, potassium ethoxide, diisopropyl ethyl amine (DIPEA), 1 ,8-diazabicylco[5.4.0]undec-7-ene (DBU), 1 ,4-diazabicyclo[2.2.2]octane (DABCO) or lithium tert-butoxide. In one embodiment the base is sodium ethoxide.
The Table lists the reaction parameters that provide optimal production of 2- ethoxycarbonylamino-5-(4-fluorobenzylamino)-nitrobenzene (a compound of formula (I)) or a salt thereof:
Table 1 Parameters and Limits for Reaction of 2-ethoxycarbonylamino-5-(4- fluorobenzylamino)-nitrobenzene with Diethylcarbonate in the presence of base
Equivalents AcOH 1.8 2.2 2.0
Reaction Temperature (°C) 15 30 22.5
Reaction Time(h) 1.5 24 6
In one embodiment the base is present in range of 1.8 to 2.2 molar equivalents.
In one embodiment the base is neutralized with an acid. In one embodiment the acid is any organic or mineral acid. In one embodiment the acid is acetic acid. In one embodiment the acid is present in range of 1.8 to 2.2 molar equivalents.
In one embodiment diethylcarbonate is present in the range of 5 to 7 molar equivalents. In one embodiment the reaction temperature is in the range 15 to 30°C.
In one embodiment the reaction time is in the range 1.5 to 24 hours.
The compound of formula (II) may be prepared by the reaction of 4-fluorobenzaldehyde and 4-amino-2-nitroaniline followed by reduction using standard procedures for example using NaBH4 in solution in NaOH or n-methylpyrrolidine (NMP). Other common boron, aluminium or metal hydride reducing agents may be used.
A solvent used for the above reaction can be selected from an alcohol, for example ethanol or isopropanol (I PA). The alcohol may be denatured. The compound of formula (II) may be isolated in crystalline form by the addition of a counter solvent for example water.
It will be understood that the preparation of a compound of formula (II) involves the in situ preparation of 4-(4-fluorobenzylideneamino)-2-nitroaniline (compound of formula (III)
Isolation of the compound of formula (III) is not necessary, although this is included in the scope of this invention. Judicious selection of the solvent for the first step of this reaction, I PA or ethanol, allows the processes to be carried out sequentially in the same vessel.
In a further embodiment of the present invention there is provided a process for the preparation of a compound of formula (I) or a salt thereof, which comprises the following steps: reaction of 4-fluorobenzaldehyde and 4-amino-2-nitroaniline followed by reduction using standard procedures to produce a compound of formula (II); and
reacting a compound of formula (II) with diethylcarbonate in the presence of a base to produce a compound of formula (I), or a salt thereof.
In one embodiment of the present invention there is provided a process for the preparation of retigabine, or a salt thereof, which comprises the following steps: reacting a compound of formula (II) with diethylcarbonate in the presence of a base to produce a compound of formula (I), or a salt thereof; and reduction of compound of formula (I) using standard procedures to produce retigabine;
and optionally preparing a salt thereof.
The present process for the preparation of retigabine allows for a better control of impurity levels and has fewer steps providing better cost of goods.
In one embodiment of the present invention there is provided a process for the preparation of retigabine, or a salt thereof, which comprises the following steps:
(i) reaction of 4-fluorobenzaldehyde and 4-amino-2-nitroaniline followed by reduction using standard procedures to produce a compound of formula
(II);
(ii) reacting a compound of formula (II) with diethylcarbonate in the presence of a base to produce a compound of formula (I), or a salt thereof; and
(iii) reduction of compound of formula (I) using standard procedures to produce retigabine;
(iv) and optionally preparing a salt thereof. The preparation of retigabine from a compound of formula (I) or the preparation of a compound of formula (III) can be carried out using standard procedures for reduction for example using H2 on Platinum (Pt)/Vanadium (V) on carbon or use H2/Raney nickel. Polymorphic forms A, B and C of retigabine are disclosed in WO98/031663 (US
6538151), incorporated in its entirety. Specifically incorporated are the characterising data for the polymorphic forms and their methods of preparation.
The above processes for the preparation of retigabine may further include the preparation of retigabine polymorphic Form A, Form B or Form C, preferably Form A.
In any preparation of retigabine in polymorphic form, a retigabine solvent mixture may be seeded with retigabine of the desired polymorphic form in order to enhance recrystallisation.
In one embodiment of the present invention there is therefore provided a process for the preparation of polymorphic Forms A, B or C of retigabine which comprises the following steps: reacting a compound of formula (II) with diethylcarbonate with a base to produce a compound of formula (I), or a salt thereof; and
reduction of compound of formula (I) using standard procedures to produce retigabine; and optionally
preparing retigabine in polymorphic form optionally including the additional step of seeding the retigabine solvent mixture with retigabine Polymorphic Form A, B or C.
In one embodiment of the present invention there is therefore provided a process for the preparation of polymorphic Forms A, B or C of retigabine which comprises the following steps: reaction of 4-fluorobenzaldehyde and 4-amino-2-nitroaniline followed by reduction using standard procedures to produce a compound of formula (II);
reacting a compound of formula (II) with diethylcarbonate with a base to produce a compound of formula (I), or a salt thereof; and reduction of compound of formula (I) using standard procedures to produce retigabine; and optionally
preparing retigabine in polymorphic form optionally including the additional step of seeding the retigabine solvent mixture with retigabine Polymorphic Form A, B or C.
Retigabine and the compounds of formulas (I), (II) and (III), can form acid addition salts thereof. Suitable pharmaceutically acceptable salts will be apparent to those skilled in the art and include those described in J. Pharm. Sci., 1977, 66, 1-19, such as acid addition salts formed with inorganic acids e.g. hydrochloric, hydrobromic, sulfuric, nitric or phosphoric acid; and organic acids e.g. succinic, maleic, acetic, fumaric, citric, tartaric, benzoic, p-toluenesulfonic, methanesulfonic or naphthalenesulfonic acid.
Examples
Stage 1 Stage 1 con't
Stage 2 Stage 3
Crude Retigabine
Stage 4
The following abbreviations are defined herein.
I PA - isopropanol or 2-propanol
IMS - Industrial methylated spirit
LOD- limit of detection.
Stage 1 - Preparation of 4-(4-fluorobenzylamino)-2-nitroaniline.
4-Amino-2-nitroaniline (1.0 equiv.; 1.0 wt) was dissolved in I PA. The mixture was warmed to 75 °C and 4-fluorobenzaldehyde (1.05 equiv.; 0.285 wt) was added. When formation of imine was complete, a solution of NaBH4 in 0.1 % NaOH was added. After complete reduction of the imine at 75 °C, water was added to the hot mixture. The mixture was cooled and acetone (0.2 vol) was added. The mixture was cooled to 15 °C and held for at least 30 minutes. Dark brown crystalline solid was collected, washed with water, and dried under vacuum at 50 - 55 °C.
Percent yield range observed: 79 - 85%
Stage 2- Preparation of 2-ethoxycarbonylamino-5-(4-fluorobenzylamino)- nitrobenzene.
A vessel was charged with 4-(4-fluorobenzylamino)-2-nitroaniline (1.0 equiv.; 1.0 wt), NaOEt (2.0 equiv.; 0.52 wt), and diethylcarbonate (DEC) (7 vol). The heterogeneous mixture was stirred at 20-25 °C for 1.5 h or until complete by HPLC. Acetic acid (2.0 equiv) was charged and the mixture was heated to 40-50 °C. H20 and n-BuOH were added to the mixture and the layers were separated. The organic mixture was concentrated under vacuum and n-BuOH was added and distilled via constant volume distillation. The distillation was continued until the desired ratio was obtained. n-BuOH was added and the mixture was adjusted to 60-65 °C to dissolve all solids. The batch temperature was adjusted to 50°C and seeded with 2-ethoxycarbonylamino-5-(4- fluorobenzylamino)-nitrobenzene. The suspension was stirred at 50°C and then cooled to 0°C. The solid was filtered and washed with cold n-BuOH. The solid was dried under reduced pressure at 20-40 °C.
Percent yield range observed: 80-88% Stage 3- Preparation of retigabine
A pressure vessel was charged with 2-ethyoxycarbonylamino-5-(4-fluorobenzylamino)- nitrobenzene, 1 kg (1 wt), and the catalyst, 1 % Pt + 2 % V/C, 50 g (0.05 wt). The vessel was pressure test with nitrogen to 6 barg. The reactor was charged with denatured ethanol, 10 L (10 vol), and the stir rate was set to > 450 rpm. The vessel was pressure purged 3 times with nitrogen to 2 barg. The reaction mixture was heated to 50 °C under reactor control. Once an internal temperature of 50 °C was achieved, agitation was discontinued and the reactor purged three times with hydrogen to 2 barg. Following the third hydrogen purge and once the vessel reached 2 barg again, hydrogen flow control was initiated and the agitator activated. The reactor contents were aged for 2 hours. The reaction was heated to 70 °C and stirred for an additional 1 hour at 70° C. Once complete, the reaction mixture was filtered. The filtrate was transfer to a second 20 L vessel. The reactor was rinsed with denatured ethanol, 3 L (3 vol) and heated to > 55 °C. The rinse was filtered and the solution transferred to the second 20-L vessel. Once the batch temperature dropped below 30 °C, a vacuum was established, 100 mbar (solution will boil at ~ 29 °C), and the solution concentrated to 7.5 L (7.5 vol). The solution was heated to 65 °C and aged until dissolution has occurred. The batch was cooled to 50 °C and seeded with retigabine (API), 5 g (0.005 wt) slurried in denatured ethanol, 20 ml_ (0.02 vol). After charging the seed, the solution was immediately cooled to 40 °C over 40 minutes, then aged for 60 min. The solution was cooled to 0 °C over 2 hours. The heterogeneous solution was stirred at 0 °C for 1 hour. The batch was milled, isolated and dried. The slurry was transferred to a filter and filtered. The wet cake was transferred to the vacuum oven and dried at 30-40 °C until the LOD indicated < 0.5 % wt. loss (120 °C for 15 minutes).
Percent yield range observed: 70-90 %
Preparation of Polymorph A
A reaction vessel was charged with denatured ethanol (7.0 volumes) and retigabine (1 wt) was added and the heated to 65-75 °C to dissolve, and stirred for 30 minutes. The solution was filtered to clarify with the temperature maintained above 60 °C throughout the filtration process to avoid precipitation of product. The reactor was rinsed and lined with 1 volume of denatured ethanol. After filtration, the filtered solution was reheated to 60-70 °C to ensure dissolution. The solution was cooled to 54-57 °C (55 °C) and temperature of the contents stabilized. The solution was cooled to 48-53 °C, and upon reaching the desired temperature range, seeded with 0.5 wt% of Form A wet-milled seeds as a slurry in denatured ethanol (0.02 vol) at room temperature. The seed pot was washed with 0.02 vol denatured ethanol. The slurry was cooled to 30-40 °C (35 °C) and held for 60 minutes. The slurry was then cooled to -5 °C to 5 °C at up to 0.5 °C/min.
The particle size was reduced using a wet mill on a reactor recirculation loop. When the target particle size was reached, the batch was heated to about 35 °C and then cooled to 0 °C and held for 30 min up to 24 hours. The slurry was charged to a filter dryer and settled for 30 min. The mother liquors were removed and the filter cake was washed with cold (0 °C ethanol wash) (2.0 volumes of denatured ethanol). Retigabine was isolated from the filter drier and was placed in appropriate containers.
Percent yield range observed: 85-89 %

Claims

Claims
1. A process for the production of 2-ethoxycarbonylamino-5-(4- fluorobenzylamino)-nitrobenzene a compound of formula (I)) or a salt thereof:
which comprises reacting 4-(4-fluorobenzylamino)-2-nitroaniline (the compound of formula (II))
with diethylcarbonate in the presence of a base and optionally preparing a salt thereof.
2. A process as claimed in claim 1 for the preparation of a compound of formula (I) or a salt thereof, which further comprises reaction of 4-fluorobenzaldehyde and 4- amino-2-nitroaniline followed by reduction using standard procedures to produce a compound of formula (II).
3. A process for the preparation of retigabine, or a salt thereof, which comprises the following steps:
(i) reacting a compound of formula (II) with diethylcarbonate in the presence of a base to produce a compound of formula (I), or a salt thereof; and
(ii) reduction of compound of formula (I) using standard procedures to produce retigabine;
(iii) and optionally preparing a salt thereof. 4. A process as claimed in claim 3 for the preparation of retigabine, or a salt thereof, which further comprises reaction of 4-fluorobenzaldehyde and 4-amino-2- nitroaniline followed by reduction using standard procedures to produce a compound of formula (II).
EP12700199.8A 2011-01-18 2012-01-16 Process for the preparation of retigabine Withdrawn EP2665702A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP12700199.8A EP2665702A1 (en) 2011-01-18 2012-01-16 Process for the preparation of retigabine

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
PCT/EP2011/050633 WO2011089126A2 (en) 2010-01-20 2011-01-18 Novel composition
US201161509802P 2011-07-20 2011-07-20
PCT/EP2012/050559 WO2012098075A1 (en) 2011-01-18 2012-01-16 Process for the preparation of retigabine
EP12700199.8A EP2665702A1 (en) 2011-01-18 2012-01-16 Process for the preparation of retigabine

Publications (1)

Publication Number Publication Date
EP2665702A1 true EP2665702A1 (en) 2013-11-27

Family

ID=45657084

Family Applications (1)

Application Number Title Priority Date Filing Date
EP12700199.8A Withdrawn EP2665702A1 (en) 2011-01-18 2012-01-16 Process for the preparation of retigabine

Country Status (1)

Country Link
EP (1) EP2665702A1 (en)

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
FUJITA S I ET AL: "Synthesis of 1,3-dialkylurea from ethylene carbonate and amine using calcium oxide", JOURNAL OF MOLECULAR CATALYSIS A: CHEMICAL, ELSEVIER, AMSTERDAM, NL, vol. 230, no. 1-2, 6 April 2005 (2005-04-06), pages 43 - 48, XP027658359, ISSN: 1381-1169, [retrieved on 20050406] *
SACHIN R. JAGTAP ET AL: "Synthesis of 1,3-Disubstituted Symmetrical/Unsymmetrical Ureas via Cs2CO3 -Catalyzed Transamination of Ethylene Carbonate and Primary Amines", SYNTHETIC COMMUNICATIONS, vol. 39, no. 12, 22 May 2009 (2009-05-22), PHILADELPHIA, PA; US, pages 2093 - 2100, XP055288575, ISSN: 0039-7911, DOI: 10.1080/00397910802638503 *
See also references of WO2012098075A1 *

Similar Documents

Publication Publication Date Title
US11629159B2 (en) Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use
AU2002366383B2 (en) Polymorphs of clopidogrel hydrogensulfate
EP3248983A1 (en) Crystal form a of obeticholic acid and preparation method therefor
US20150183767A1 (en) Novel polymorphs of azilsartan medoxomil
US9102593B2 (en) Process for the preparation of retigabine
CN111217781B (en) Beraprost-314D crystal and preparation method thereof
CN104829590B (en) Method for purifying trelagliptin
CN104703967B (en) Refining method of fluvoxamine free base and preparation method of high-purity fluvoxamine maleate using same
WO2017167233A1 (en) New crystalline form of obeticholic acid and preparation method therefor
US12459965B2 (en) Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use
EP2665702A1 (en) Process for the preparation of retigabine
US20130211091A1 (en) Crystalline forms of maraviroc phosphate and process for maraviroc amorphous form
CN116444387A (en) Preparation method of high-purity tetracaine bulk drug
CA2811912A1 (en) Novel polymorphs of febuxostat
CN117658900B (en) Preparation method of tetrahydronaphthyridine compound and intermediate thereof
US8093384B2 (en) Processes for the preparation of alfuzosin
JP7033662B2 (en) How to prepare large-scale trimidone
WO2014049609A2 (en) Novel salts of vilazodone
CN115785089A (en) Method for synthesizing riociguat impurity C
CN112574218A (en) Synthesis method of indole or azabenzopyrrole compound
CN106083614A (en) A kind of preparation method of metoprolol salt

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20130717

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAX Request for extension of the european patent (deleted)
17Q First examination report despatched

Effective date: 20160720

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

INTG Intention to grant announced

Effective date: 20180124

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20180605